Rheumatology

Latest News

eye on pharma banner
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22nd 2025

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.

biosimilar business deal | Image credit: Mongkolchon - stock.adobe.com
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

April 14th 2025

AI biosimilar syringe | Image credit: Phichaphat - stock.adobe.com
Early Success of Adalimumab Biosimilars Featured at AMCP 2025

April 5th 2025

anti-tnf biologics and savings in Europe | Image credit: gopixa - stock.adobe.com
Smart Tendering Policies Unlock Greater Biosimilar Savings

March 20th 2025

AI generated ustekinumab pens | Image credit: Napat - stock.adobe.com
More Ustekinumab Biosimilars Join US Market Share Fight

March 13th 2025

Video Series
Video Interviews
Podcasts
CFB podcast banner
CFB podcast banner
CFB podcast banner
CFB podcas
CFB podcast banner
CFB podcast banner
cfb podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.